Kim Jae, Raz Dan, Jablons David
Department of Surgery, University of California San Francisco Cancer Center, San Francisco, CA 94143-1724, USA.
Clin Lung Cancer. 2008 Feb;9 Suppl 1:S6-12. doi: 10.3816/clc.2008.s.002.
Despite recent advances in therapy for lung cancer, median survival remains poor. Cancer vaccines might meet the unmet need for new and effective therapies with low toxicity. A better understanding of the immunology of cancer has led to novel strategies for vaccine delivery, including the use of immunogenic adjuvant agents, genetic modification of tumor cells to produce cytokines, viral vectors, and the use of antigen-presenting cells. A number of these strategies have been studied in clinical trials for lung cancer. This review discusses the rationale for vaccine therapy in lung cancer, strategies for vaccine delivery, and clinical trials of vaccines in lung cancer.
尽管肺癌治疗最近取得了进展，但中位生存期仍然很差。癌症疫苗可能满足对低毒性新型有效疗法的未满足需求。对癌症免疫学的更好理解催生了疫苗递送的新策略，包括使用免疫原性佐剂、对肿瘤细胞进行基因改造以产生细胞因子、病毒载体以及使用抗原呈递细胞。其中一些策略已在肺癌临床试验中进行了研究。本综述讨论了肺癌疫苗治疗的基本原理、疫苗递送策略以及肺癌疫苗的临床试验。
